CY1936A - Herpes simplex vaccine comprising HSV glycoprotein gD and 3 deacylated monophosphoryl lipid A - Google Patents

Herpes simplex vaccine comprising HSV glycoprotein gD and 3 deacylated monophosphoryl lipid A

Info

Publication number
CY1936A
CY1936A CY193692A CY193692A CY1936A CY 1936 A CY1936 A CY 1936A CY 193692 A CY193692 A CY 193692A CY 193692 A CY193692 A CY 193692A CY 1936 A CY1936 A CY 1936A
Authority
CY
Cyprus
Prior art keywords
herpes simplex
monophosphoryl lipid
deacylated monophosphoryl
hsv glycoprotein
simplex vaccine
Prior art date
Application number
CY193692A
Other languages
English (en)
Inventor
Myriam Francotte
Jean-Paul Prieels
Moncef Slaoui
Nathalie Garcon-Johnson
Original Assignee
Smithkline Beecham Biolog
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10691946&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1936(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Smithkline Beecham Biolog filed Critical Smithkline Beecham Biolog
Publication of CY1936A publication Critical patent/CY1936A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CY193692A 1991-03-21 1992-03-17 Herpes simplex vaccine comprising HSV glycoprotein gD and 3 deacylated monophosphoryl lipid A CY1936A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9105992A GB9105992D0 (en) 1991-03-21 1991-03-21 Vaccine
PCT/EP1992/000592 WO1992016231A1 (fr) 1991-03-21 1992-03-17 Vaccin de l'herpes simplex comprenant une glycoproteine gd du hsv et le lipide a de monophosphoryle 3-deacyle

Publications (1)

Publication Number Publication Date
CY1936A true CY1936A (en) 1992-03-17

Family

ID=10691946

Family Applications (1)

Application Number Title Priority Date Filing Date
CY193692A CY1936A (en) 1991-03-21 1992-03-17 Herpes simplex vaccine comprising HSV glycoprotein gD and 3 deacylated monophosphoryl lipid A

Country Status (33)

Country Link
US (1) US6027730A (fr)
EP (1) EP0576478B2 (fr)
JP (1) JP3530526B2 (fr)
KR (1) KR100224329B1 (fr)
CN (2) CN1058191C (fr)
AP (1) AP298A (fr)
AT (1) ATE129160T1 (fr)
AU (1) AU650521B2 (fr)
BR (1) BR9205745A (fr)
CA (1) CA2106492C (fr)
CY (1) CY1936A (fr)
CZ (1) CZ280505B6 (fr)
DE (1) DE69205566T3 (fr)
DK (1) DK0576478T4 (fr)
ES (1) ES2081102T5 (fr)
FI (1) FI107881B (fr)
GB (1) GB9105992D0 (fr)
GR (1) GR3017884T3 (fr)
HU (1) HU218025B (fr)
IE (1) IE69560B1 (fr)
IL (1) IL101290A (fr)
MA (1) MA22471A1 (fr)
MX (1) MX9201245A (fr)
MY (1) MY110086A (fr)
NO (1) NO307499B1 (fr)
NZ (1) NZ242057A (fr)
PL (1) PL170059B1 (fr)
PT (1) PT100262B (fr)
SA (1) SA92120459B1 (fr)
SK (1) SK279190B6 (fr)
WO (1) WO1992016231A1 (fr)
YU (1) YU28392A (fr)
ZA (1) ZA922011B (fr)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9105992D0 (en) * 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccine
US6197311B1 (en) 1991-07-25 2001-03-06 Idec Pharmaceuticals Corporation Induction of cytotoxic T-lymphocyte responses
GB9202933D0 (en) * 1992-02-12 1992-03-25 Smithkline Beecham Biolog Vaccines
US6620414B2 (en) 1992-03-27 2003-09-16 Smithkline Beecham Biologicals (S.A.) Hepatitis vaccines containing 3-0-deacylated monophoshoryl lipid A
CA2156525A1 (fr) * 1993-02-19 1994-09-01 Susan Dillon Compositions a base de lipide a monophosphoryle 3-o-desacyle pour des vaccins anti-grippe
JP4028593B2 (ja) * 1993-03-23 2007-12-26 グラクソスミスクライン・バイオロジカルス・ソシエテ・アノニム ３−ｏ脱アシル化モノホスホリルリピドａ含有ワクチン組成物
AU676340B2 (en) * 1993-05-25 1997-03-06 Wyeth Holdings Corporation Adjuvants for vaccines against respiratory syncytial virus
GB9326253D0 (en) * 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
AU704829B2 (en) * 1994-12-28 1999-05-06 University Of Kentucky Murine anti-idiotype antibody 3H1
US6949244B1 (en) 1995-12-20 2005-09-27 The Board Of Trustees Of The University Of Kentucky Murine monoclonal anti-idiotype antibody 11D10 and methods of use thereof
US20020041872A1 (en) 1996-04-12 2002-04-11 Malaya Chatterjee Methods of delaying development of CEA-associated tumors using anti-idiotype antibody 3H1
US6235280B1 (en) 1996-04-12 2001-05-22 Malaya Chatterjee Methods of delaying development of CEA-associated tumors using anti-idiotype antibody 3H1
US6468782B1 (en) 1996-12-05 2002-10-22 Quadrant Healthcare (Uk) Limited Methods of preserving prokaryotic cells and compositions obtained thereby
US6274143B1 (en) 1997-06-13 2001-08-14 Malaya Chatterjee Methods of delaying development of HMFG-associated tumors using anti-idiotype antibody 11D10
US6355244B1 (en) 1997-11-17 2002-03-12 University Of Kentucky Research Foundation Methods and compositions for the treatment of psoriasis
GB9819898D0 (en) * 1998-09-11 1998-11-04 Smithkline Beecham Plc New vaccine and method of use
US6692752B1 (en) * 1999-09-08 2004-02-17 Smithkline Beecham Biologicals S.A. Methods of treating human females susceptible to HSV infection
EP1588714A2 (fr) 1998-10-16 2005-10-26 GlaxoSmithKline Biologicals S.A. Produits d'adjuvant et vaccins
US7026155B2 (en) 1999-02-02 2006-04-11 Regents Of The University Of California Method of reducing bacterial proliferation
EP1104767A1 (fr) 1999-11-30 2001-06-06 Stichting Dienst Landbouwkundig Onderzoek Dérivés de mono- et disaccharides contenant esters d'acides gras et esters de sulfate
US9273326B2 (en) 2004-04-30 2016-03-01 The Brigham And Women's Hospital, Inc. Tetracycline-regulated gene expression in HSV-1 vectors
BR122016029840B1 (pt) 2004-09-22 2021-10-13 Glaxosmithkline Biologicals S.A. Composição imunogênica, método de fabricar uma composição imunogênica, e, uso da composição imunogênica
KR101916787B1 (ko) 2005-03-23 2019-01-24 글락소스미스클라인 바이오로지칼즈 에스.에이. Ｃｄ4 ｔ－세포 및/또는 개선된 ｂ－메모리 세포 반응을 유도하는 인플루엔자 바이러스 및 수중유 에멀젼 애주번트의 용도
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
TR201900418T4 (tr) 2005-12-22 2019-02-21 Glaxosmithkline Biologicals Sa Pnömokok polisakkarit konjugat aşısı.
MY148405A (en) 2006-03-30 2013-04-30 Glaxosmithkline Biolog Sa Immunogenic composition
JP5639760B2 (ja) 2006-07-17 2014-12-10 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム インフルエンザワクチン
EP3403667B1 (fr) 2006-09-26 2020-07-22 Infectious Disease Research Institute Composition de vaccin contenant un adjuvant synthétique
US20090181078A1 (en) * 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
US9452209B2 (en) 2007-04-20 2016-09-27 Glaxosmithkline Biologicals Sa Influenza vaccine
EA020817B1 (ru) 2007-06-26 2015-02-27 Глаксосмитклайн Байолоджикалс С.А. Вакцина, содержащая конъюгаты капсульных полисахаридов streptococcus pneumoniae
CA2797937C (fr) * 2009-05-22 2020-01-14 Genocea Biosciences, Inc. Vaccins contre le virus de l'herpes simplex 2 : compositions et procedes pour declencher une reponse immunitaire
SI2437753T1 (sl) 2009-06-05 2016-12-30 Infectious Disease Research Institute Sintetični glukopiranozil-lipidni adjuvansi in cepivni sestavki, ki jih vsebujejo
GB0913680D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
GB0913681D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
JP5845191B2 (ja) 2009-12-21 2016-01-20 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． 単純ヘルペスウイルスワクチン
WO2012074881A2 (fr) 2010-11-24 2012-06-07 Genocea Biosciences, Inc. Vaccins contre le virus de type 2 de l'herpès simplex: compositions et procédés pour la stimulation d'une réponse immunitaire
JP6309274B2 (ja) * 2011-03-11 2018-04-11 ターンストーン・リミテッド・パートナーシップ ヒストンデアセチラーゼ阻害剤を含むワクチン接種法
BR112013025799A2 (pt) 2011-04-08 2016-12-20 Immune Design Corp método para induzir uma resposta imune em um sujeito, e, preparação
WO2013028738A1 (fr) 2011-08-22 2013-02-28 Nanobio Corporation Vaccin contre le virus de l'herpès simplex sous forme de nanoémulsion
CA2885693C (fr) 2011-11-23 2020-07-28 Genocea Biosciences, Inc. Vaccins a acide nucleique contre le virus d'herpes simplex de type 2 : compositions et procedes pour susciter une reponse immunitaire
EP2850431B1 (fr) 2012-05-16 2018-04-18 Immune Design Corp. Vaccins contre le hsv-2
CA2897398A1 (fr) 2013-01-07 2014-07-10 Mucosal Vaccine Technologies Llc Utilisation de vaccins pour le traitement d'infections par l'herpes simplex virus type 2
JP6426706B2 (ja) 2013-04-18 2018-11-21 イミューン デザイン コーポレイション がん処置で使用するためのｇｌａ単剤療法
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
EP3519427A4 (fr) 2016-09-28 2020-03-11 Genocea Biosciences Inc. Méthodes et compositions pour le traitement d'herpès
WO2019152821A1 (fr) 2018-02-05 2019-08-08 The Brigham And Women's Hospital, Inc. Virus de l'herpès simplex 2 recombinant exprimant des antigènes de glycoprotéine b et d
WO2022152939A1 (fr) 2021-01-18 2022-07-21 Conserv Bioscience Limited Compositions immunogènes de coronavirus, méthodes et utilisations de celles-ci

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4372945A (en) * 1979-11-13 1983-02-08 Likhite Vilas V Antigen compounds
IL61904A (en) * 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
US5110587A (en) * 1981-12-24 1992-05-05 Health Research, Incorporated Immunogenic composition comprising synthetically modified vaccinia virus
US4762708A (en) * 1982-02-18 1988-08-09 University Patents, Inc. Materials and methods for herpes simplex virus vaccination
US5149660A (en) * 1982-02-18 1992-09-22 University Patents, Inc. Diagnostic reagents relating to herpes simplex virus
NZ209308A (en) * 1983-08-30 1991-08-27 Genentech Inc Vaccine against hsv involving a truncated membrane-free derivative of a membrane-bound protein
US5244792A (en) * 1984-04-06 1993-09-14 Chiron Corporation Expression of recombinant glyoprotein B from herpes simplex virus
US5171568A (en) * 1984-04-06 1992-12-15 Chiron Corporation Recombinant herpes simplex gb-gd vaccine
US4877611A (en) * 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US5554372A (en) * 1986-09-22 1996-09-10 Emory University Methods and vaccines comprising surface-active copolymers
EP0289550B1 (fr) * 1986-10-20 1996-04-10 Chiron Corporation Vaccin utilise pour le traitement therapeutique de hsv
US5149529A (en) * 1988-04-08 1992-09-22 Board Of Trustees Of Leland Chiron Corporation Compositions and treatment for herpes simplex
US4912094B1 (en) * 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
NZ230424A (en) * 1988-08-25 1992-05-26 Liposome Co Inc Liposomal composition comprising an externally disposed antigen
JP2955314B2 (ja) * 1988-10-27 1999-10-04 リージェンツ・オブ・ザ・ユニバーシティー・オブ・ミネソタ Ｉｌ―２含有リポソーム免疫アジュバント
US5597573A (en) * 1989-05-04 1997-01-28 Igen, Inc. Lipid-A analogs: new monosaccharide and disaccharide intermediates for eliciting therapeutic antibodies and for antitumor and antiviral activities
US5158939A (en) * 1989-07-21 1992-10-27 Wisconsin Alumni Research Foundation Method of stimulating the immune systems of animals and compositions useful therefor
EP0482068A1 (fr) * 1989-07-14 1992-04-29 American Cyanamid Company Cytokine et supports d'hormone pour vaccins conjugues
EP0560776B1 (fr) * 1990-08-01 2000-02-09 Research Corporation Technologies, Inc. Gene codant pour la glycoproteine d du virus de l'herpes equin type 1, son produit genetique, anticorps et leurs emplois
EP0541692B1 (fr) * 1990-08-02 1999-05-06 Chiron Corporation Vaccins contre le virus de l'herpes vp16
GB9106048D0 (en) * 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccines
US5166173A (en) * 1991-01-29 1992-11-24 Genelabs Incorporated Method of treating herpes simplex virus infection
US5196452A (en) * 1991-01-29 1993-03-23 Genelabs Incorporated Macrocyclic anti-viral compound and method
GB9105992D0 (en) * 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccine
MA22842A1 (fr) * 1992-03-27 1993-10-01 Smithkline Beecham Biolog Procede de preparation de compositions de vaccin.
ATE188613T1 (de) * 1992-06-25 2000-01-15 Smithkline Beecham Biolog Adjuvantien enthaltende impfstoffzusammensetzung
CA2156525A1 (fr) * 1993-02-19 1994-09-01 Susan Dillon Compositions a base de lipide a monophosphoryle 3-o-desacyle pour des vaccins anti-grippe
JP4028593B2 (ja) * 1993-03-23 2007-12-26 グラクソスミスクライン・バイオロジカルス・ソシエテ・アノニム ３−ｏ脱アシル化モノホスホリルリピドａ含有ワクチン組成物
AU676340B2 (en) * 1993-05-25 1997-03-06 Wyeth Holdings Corporation Adjuvants for vaccines against respiratory syncytial virus

Also Published As

Publication number Publication date
JP3530526B2 (ja) 2004-05-24
PT100262A (pt) 1993-06-30
EP0576478B1 (fr) 1995-10-18
MY110086A (en) 1997-12-31
HU9302645D0 (en) 1994-01-28
JPH06505727A (ja) 1994-06-30
ZA922011B (en) 1993-01-27
NZ242057A (en) 1993-12-23
EP0576478A1 (fr) 1994-01-05
MA22471A1 (fr) 1992-10-01
DE69205566T2 (de) 1996-04-18
FI934134L (fi) 1993-09-21
WO1992016231A1 (fr) 1992-10-01
AP9200368A0 (en) 1992-04-30
CN1201692A (zh) 1998-12-16
IL101290A0 (en) 1992-11-15
CN1058191C (zh) 2000-11-08
CN1065997A (zh) 1992-11-11
PL170059B1 (pl) 1996-10-31
SK279190B6 (sk) 1998-07-08
GB9105992D0 (en) 1991-05-08
AU650521B2 (en) 1994-06-23
NO933343D0 (no) 1993-09-20
CZ280505B6 (cs) 1996-02-14
DE69205566D1 (en) 1995-11-23
ES2081102T5 (es) 2001-09-01
CN1101226C (zh) 2003-02-12
ATE129160T1 (de) 1995-11-15
HU218025B (hu) 2000-05-28
AP298A (en) 1994-01-14
GR3017884T3 (en) 1996-01-31
AU1365792A (en) 1992-10-21
CA2106492C (fr) 2003-12-09
SK94693A3 (en) 1994-05-11
HUT67052A (en) 1995-01-30
YU28392A (sh) 1994-11-15
HK1004525A1 (en) 1998-11-27
IL101290A (en) 1996-07-23
MX9201245A (es) 1992-10-01
CZ195893A3 (en) 1994-07-13
US6027730A (en) 2000-02-22
IE69560B1 (en) 1996-10-02
PT100262B (pt) 2001-05-31
KR100224329B1 (ko) 1999-10-15
SA92120459B1 (ar) 2005-06-14
BR9205745A (pt) 1994-10-18
NO933343L (no) 1993-09-20
CA2106492A1 (fr) 1992-09-22
EP0576478B2 (fr) 2001-04-18
NO307499B1 (no) 2000-04-17
DK0576478T4 (da) 2001-07-23
DE69205566T3 (de) 2002-09-05
IE920881A1 (en) 1992-09-23
FI934134A0 (fi) 1993-09-21
DK0576478T3 (da) 1995-12-04
FI107881B (fi) 2001-10-31
ES2081102T3 (es) 1996-02-16

Similar Documents

Publication Publication Date Title
CY1936A (en) Herpes simplex vaccine comprising HSV glycoprotein gD and 3 deacylated monophosphoryl lipid A
SG48375A1 (en) Hepatitis vaccines containing 3-0 deacylated monophosphoryl lipid a
SG48309A1 (en) Vaccine compositions containing 3-0 deacylated monophosphoryl lipid a
AP9100332A0 (en) Vaccines
EP0241655A3 (en) Extended raster operating in a display system
GB2264606B (en) Image stability in telecines
GB2275401B (en) A graphic coloring system in a graphic display system
GB8914400D0 (en) 3-d image and sign system
GB9224374D0 (en) A take-off and/or landing system
AU2968892A (en) Vaccines based on modified type 1 bovine herpesviruses
IL102290A0 (en) Ccv vaccine and its preparation
GB9114714D0 (en) Herpesvirus vaccine
ZA923273B (en) Herpesvirus particles and vaccine
GB9106152D0 (en) Free-standing greetings card display unit
GB9002545D0 (en) 3-d image and sign system
GB9204320D0 (en) Herpesvirus particles and vaccine
GB9119167D0 (en) Vaccines
GB9124390D0 (en) Vaccines
GB9105993D0 (en) Vaccines
GB9121208D0 (en) Vaccines
GB9110067D0 (en) Vaccines
ZA926088B (en) Vaccines
GB9116065D0 (en) Sheet delivery system